by MM360 Staff | Jan 23, 2026 | Publications
EClinicalMedicine. 2026 Jan 8;91:103750. doi: 10.1016/j.eclinm.2025.103750. eCollection 2026 Jan. ABSTRACT BACKGROUND: Diagnostic advancements and classification updates appear to have reshaped the natural history of smoldering multiple myeloma (SMM), though this...
by MM360 Staff | Jan 23, 2026 | Publications
Front Oncol. 2026 Jan 6;15:1729177. doi: 10.3389/fonc.2025.1729177. eCollection 2025. ABSTRACT Daratumumab, a CD38-targeting monoclonal antibody, is a key component of therapy for both newly diagnosed and relapsed or refractory multiple myeloma. By depleting...
by MM360 Staff | Jan 23, 2026 | Publications
Front Oncol. 2026 Jan 6;15:1747354. doi: 10.3389/fonc.2025.1747354. eCollection 2025. ABSTRACT OBJECTIVE: To conduct a comprehensive comparison of the efficacy, safety, and cost-effectiveness of denosumab versus zoledronic acid in patients with bone metastases from...
by MM360 Staff | Jan 10, 2026 | Publications
Hematology. 2026 Dec;31(1):2613505. doi: 10.1080/16078454.2026.2613505. Epub 2026 Jan 8. ABSTRACT Objectives: The introduction of novel therapies has markedly improved the prognosis of multiple myeloma (MM), yet relapse remains common. For patients with relapsed or...
by MM360 Staff | Jan 4, 2026 | Publications
Br J Haematol. 2026 Jan 2. doi: 10.1111/bjh.70323. Online ahead of print. ABSTRACT High-dose melphalan followed by autologous stem cell transplantation (ASCT) is the standard of care for eligible patients with newly diagnosed multiple myeloma (NDMM). A substantial...
by MM360 Staff | Dec 15, 2025 | Publications
Curr Res Transl Med. 2025 Dec 2;74(1):103559. doi: 10.1016/j.retram.2025.103559. Online ahead of print. ABSTRACT BACKGROUND: Treatment of transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM) remains challenging due to age, frailty, and comorbidities....
